Price movement over the last 24 hours
Alcon AG vs VanEck Rare Earth/Strategic Metals — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while VanEck Rare Earth/Strategic Metals trades at $79.5. The key difference: Alcon AG pays a 0.54% dividend while VanEck Rare Earth/Strategic Metals pays none, and VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | REMX | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Sector/Thematic |
52-Week High | $92.22 | $109.53 |
52-Week Low | $62.02 | $41.94 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
REMX trades at $85.34, down 1.59% today, with a bearish technical signal driven by moving averages. The ETF is positioned in the rare earth and strategic metals sector, benefiting from geopolitical tensions and supply chain shifts. Recent news highlights strong institutional interest in materials and commodities, with REMX recognized for AI infrastructure and defense exposure. Key support is at $84, with resistance at $86.
Outlook is mixed; rare earth demand is rising due to AI and energy transitions, but high concentration and volatility pose risks. Investment opportunity lies in commodity cycle exposure, yet investors face geopolitical and inflation uncertainties. Wall Street sentiment is cautious despite thematic tailwinds.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →